Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00459
UPID:
P85B_HUMAN
Alternative names:
Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta
Alternative UPACC:
O00459; Q5EAT5; Q9UPH9
Background:
Phosphatidylinositol 3-kinase regulatory subunit beta, also known as the 85 kDa regulatory subunit beta, plays a pivotal role in cell signaling pathways. It is a key component of the PI3K complex, involved in the phosphorylation of PtdIns(4,5)P2 to generate PIP3. This process is crucial for cell growth, survival, proliferation, motility, and morphology, highlighting its significance in cellular functions.
Therapeutic significance:
The protein is linked to Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, a condition characterized by brain and limb abnormalities. Understanding the role of Phosphatidylinositol 3-kinase regulatory subunit beta could open doors to potential therapeutic strategies for this syndrome and related disorders.